Skip to content

Ketamine: all studies

Page 421 of 448: studies 4,201 to 4,210 of 4,475, newest first. Back to the ketamine overview

Research

Psychedelics Promote Structural and Functional Neural Plasticity

Cell Reports June 1, 2018 Calvin Ly, Alexandra C. Greb, Lindsay P. Cameron et al. 1,158 citations

Atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology of depression and related disorders. The ability to promote both structural and functional plasticity in the PFC has been hypothesized to underlie the fast-acting antidepressant properties of the dissociative anesthetic ketamine. Here, we report that, like ketamine, serotonergic psychedelics are capable of...

DOI: 10.1016/j.celrep.2018.05.022 (opens in new tab) Neuroplasticity Structural plasticity Pi3k/akt/mtor pathway Prefrontal cortex +4

Effects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression

ACS Chemical Neuroscience April 17, 2018 Lindsay P. Cameron, Charlie J. Benson, Lee E. Dunlap et al. 168 citations

Depression and anxiety disorders are debilitating diseases resulting in substantial economic costs to society. Traditional antidepressants often take weeks to months to positively affect mood and are ineffective for about 30% of the population. Alternatives, such as ketamine, a dissociative anesthetic capable of producing hallucinations, and the psychoactive tisane ayahuasca, have shown great...

Experts Remain Enthusiastic About NMDA-Targeting Antidepressants

Psychiatric News April 4, 2018 Nick Zagorski

Though several promising investigational compounds that regulate glutamate signaling have faltered in recent clinical studies, upcoming data on esketamine and rapastinel may turn the tide. When the anesthetic ketamine was first shown to have strong and rapid antidepressant properties back in 2000, it triggered a wave of excitement in the psychiatric community. Studies of mood disorders have...

Convergent Mechanisms Underlying Rapid Antidepressant Action.

CNS Drugs March 2018 Panos Zanos, Scott M. Thompson, Ronald S. Duman et al.

Traditional pharmacological treatments for depression have a delayed therapeutic onset, ranging from several weeks to months, and there is a high percentage of individuals who never respond to treatment. In contrast, ketamine produces rapid-onset antidepressant, anti-suicidal, and anti-anhedonic actions following a single administration to patients with depression. Proposed mechanisms of the...

Novel treatment options in depression and psychosis

Neuropsychiatric Disease and Treatment March 1, 2018 Eva Češková, Petr Šilhán

Eva Ceskova, Petr Silhan Department of Psychiatry, University Hospital Ostrava, Ostrava, Czech Republic Abstract: In spite of tremendous development in central nervous system research, current treatment is suboptimal, especially in severe mental disorders. In medicine, there are two main methods of improving the health care provided: seeking new treatment procedures and perfecting (optimizing)...

DOI: 10.2147/ndt.s157475 (opens in new tab) Aripiprazole Lurasidone Schizophrenia object-oriented programming Intensive care medicine +1

Alteration of Depressive-like Behaviors by Psilocybe cubensis Alkaloid Extract in Mice: the Role of Glutamate Pathway

SHILAP Revista de lepidopterología March 1, 2018 Elaheh Mahmoudi, Mehrdad Faizi, Reza Hajiaghaee et al. 14 citations

Background and objectives: Considering the increasing prevalence of depression, many studies are launched to investigate new antidepressant treatments. The present research has shown how psilocybin as an active compound of Psilocybe cubensis (Earle) Singer extract (PCE) can change the parameters related to depression and anxiety in animal models. Both serotonin (5-hydroxytryptamine: 5-HT) and...

Skin picking disorder comorbid with ADHD successfully treated with methylphenidate

Revista Brasileira de Psiquiatria February 24, 2018 Camila Bernardes, P. Mattos, B. P. Nazar

Rev Bras Psiquiatr. 2018;40:110 Brazilian Journal of Psychiatry 00000000-0002-7316-1185 | doi:10.1590/1516-4446-2017-2380 Singh et al. reported that two or three weekly 40 min i.v. infusions of ketamine (0.5 mg/kg) are safe and effective for maintaining an acute response to ketamine during one month of treatment for resistant depression (TRD). We present herein the results of an open label...

Glutamatergic Modulators in Depression

Harvard Review of Psychiatry February 21, 2018 Ioline D. Henter, Rafael Teixeira de Sousa, Carlos A. Zarate 94 citations

LEARNING OBJECTIVE: After participating in this activity, learners should be better able to evaluate the evidence supporting the antidepressant effects of glutamatergic modulators.Both preclinical and clinical studies have implicated glutamatergic system dysfunction in the pathophysiology of mood disorders such as bipolar depression and major depressive disorder. In particular, rapid reductions...

DOI: 10.1097/hrp.0000000000000183 (opens in new tab) Glutamatergic Dextromethorphan Pharmacology Nmda receptor +5

Loss of consciousness is related to hyper-correlated gamma-band activity in anesthetized macaques and sleeping humans.

Neuroimage February 15, 2018 Michał Bola, Adam B. Barrett, Andrea Pigorini et al.

Loss of consciousness can result from a wide range of causes, including natural sleep and pharmacologically induced anesthesia. Important insights might thus come from identifying neuronal mechanisms of loss and re-emergence of consciousness independent of a specific manipulation. Therefore, to seek neuronal signatures of loss of consciousness common to sleep and anesthesia we analyzed...

Combined NMDA Inhibitor Use in a Patient With Multisubstance-induced Psychotic Disorder

Journal of Addiction Medicine February 4, 2018 Matteo Caloro, Giuseppa Calabrò, Eleonora de Pisa et al. 9 citations

: Novel psychoactive substance use is a major social concern. Their use may elicit or uncover unpredictably as yet undescribed clinical pictures. We aimed to illustrate a multisubstance use case indistinguishable from paranoid schizophrenia, so to alert clinicians on possibly misdiagnosing substance-induced psychotic disorders. CASE REPORT: We describe a case of a 32-year-old man who started at...